Analytical Data
-
Gene name
CLEC9A
- Application
-
Alternative Names
C-type lectin domain family 9 member A; CD370; CLEC9A; UNQ9341/PRO34046
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
CLEC9A
-
Expression Region
1-241aa
-
AA Sequence
MHEEEIYTSLQWDSPAPDTYQKCLSSNKCSGACCLVMVISCVFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALLNFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQNRESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFITGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLPAERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV
-
Molecular Weight
53.7 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC9A, or C-type lectin domain family 9 member A, is a receptor primarily expressed on the surface of dendritic cells, which plays a crucial role in the immune system by recognizing and binding to various pathogens. Research into CLEC9A recombinant proteins has gained traction due to its potential applications in immunotherapy and vaccine development. The protein has been shown to facilitate the uptake of antigenic material and enhance T cell activation, making it an attractive target for designing innovative therapeutic strategies against cancers and infectious diseases. Researchers aim to manipulate CLEC9A’s ability to present antigens to stimulate the immune response, thereby improving the efficacy of vaccines. Moreover, the use of recombinant CLEC9A proteins could enable the development of targeted therapies that harness the body’s own immune system to fight diseases more effectively. As the understanding of CLEC9A's molecular mechanisms deepens, it paves the way for novel approaches to harness dendritic cell biology in the context of both vaccine design and cancer immunotherapy, underlining the importance of this receptor in enhancing immune responses. Overall, the study of CLEC9A recombinant proteins holds significant promise for advancing the field of immunology and developing next-generation therapeutic modalities that could address the limitations of current treatments.
